All clinical trials are not created equal: The dilemma of HEAAL

European Journal of Heart Failure

Volumn 10, Issue 9, 2008, Pages 817-818

  Hauptman, Paul J ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dose; Losartan; Randomised clinical trial

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN;

CLINICAL RESEARCH; EDITORIAL; HEART EJECTION FRACTION; MEDICAL LITERATURE; PATIENT CARE; PRIORITY JOURNAL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEART FAILURE; HUMANS; LOSARTAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 51449120250     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.06.017     Document Type: Editorial

References (23)

1. Orwell G. Animal Farm, p. 123. New York: Harcourt Brace edition/First Plume printing, 1983.
2. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 23 (1987) 1429-1435
3. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314 (1986) 1547-1552
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
5. Packer M., Coats A.J.S., Fowler M.B., et al., For the Carvedilol Prospective Randomized Cumulative Survival Study Group (COPERNICUS). Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
6. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
7. Pitt B., White H., Nicolau J., et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46 (2005) 425-431
8. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
9. Heiat A., Gross C.P., and Krumholz H.M. Representation of the elderly, women and minorities in heart failure clinical trials. Arch Int Med 162 (2002) 1682-1688
10. Masoudi F.A., Havranek E.P., Wolfe P., et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 146 (2003) 250-257
11. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET). Lancet 362 (2003) 7-13
12. Willenheimer R., van Veldhuisen D.J., Silke B., et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112 (2005) 2426-2435
13. Packer M., Poole-Wilson P.A., Armstrong P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100 (1999) 2312-2318
14. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325 (1991) 1468-1475
15. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
16. Konstam MA, Poole-Wilson PA, Dickstein K, et al. Design of the heart failure endpoint evaluation of AII-antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor. Eur J Heart Fail 2008-this issue.
17. Pitt B., Segal R., Martinez F.A., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349 (1997) 747-752
18. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 (2000) 1582-1587
19. Dickstein K., Kjekshus J., and OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360 (2002) 752-760
20. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
21. Dickstein K. What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?. Am Heart J 145 (2003) 754-757
22. Furberg C.D., Herrington D.M., and Psaty B.M. Are drugs within a class interchangeable?. Lancet 354 (1999) 1202-1204
23. Furberg C.D., and Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable?. J Am Coll Cardiol 37 (2001) 1456-1460